Skip to main content
. Author manuscript; available in PMC: 2022 Feb 11.
Published in final edited form as: AAPS PharmSciTech. 2021 Feb 11;22(2):71. doi: 10.1208/s12249-021-01928-9

Figure 3.

Figure 3.

Schematic of the general mode of action of GBM targeting NP treatments. (A) NPs in blood circulation cross the BBB via RMT. (B and C) NPs with specific-targeting ligands (e.g. transferrin or angiopep-2) conjugated to their surface reach the GBM cells where they can be taken up by receptor-mediated endocytosis which will ultimately lead to GBM cell death (not shown).